Recent Research

Abraham I, et al. – Research published in Blood Advances reviews health disparities among Non-Hispanic Black and Hispanic patients with acute myeloid leukemia (AML). Results show a novel structural racism variable accounts for nearly all disparity in AML survival in this first-of-its-kind analysis.

Maakaron JE, et al.  – Research published in Bone Marrow Transplantation suggests that age alone should not be a deciding factor when determining candidacy for transplant in adult patients with acute myeloid leukemia (AML), and transplant should be considered a standard of care option for patients of all ages with AML in first complete remission. This study showed that all age groups reached comparable 3-year overall survival, and differences between younger and older groups were better explained by comorbidities and other factors than age.

 

John M. Pagel, MD, PhD, Megan Othus, PhD, et al – Barriers to human leukocyte antigen (HLA) typing and cytogenetic testing can significantly impact the overall survival of patients newly diagnosed with acute myeloid leukemia (AML).  In this landmark study, a concerted effort to address those issues and streamline the initiation of donor identification and referral for hematopoietic cell transplant (HCT) consultation in early disease state led to a higher CR1 transplantation rate and improved 2-year overall survival.

Shimoni A, et al., Biol Blood Marrow Transplant – In an analysis of 1134 patients age 50 or older with acute myeloid leukemia (AML), two-year hematopoietic cell transplant (HCT) survivors experienced comparable 10-year leukemia-free survival (LFS) and overall survival (OS) with matched sibling or unre-lated donors.